Our Advantage

DISCOVERY

a novel approach to liquid biopsy.

We are looking where others are not.

Exai is developing liquid biopsy tests that detect a new class of cancer-associated small non-coding RNA biomarkers, termed orphan non-coding RNAs (oncRNAs). The RNA content of the transcriptome provides a more dynamic and comprehensive view of actionable cancer biology than the genome’s DNA content. oncRNA-based tests have high sensitivity and specificity because oncRNAs are abundant in the blood of patients with cancer and largely absent in people without cancer.

In studies of more than 16,000 patients, Exai has identified hundreds of thousands of unique oncRNAs, which comprise an extensive catalog that is enabling Exai to develop novel RNA-based tests for early cancer detection.

Read the Publication >

INSIGHTS

AI empowers oncRNAs to reveal dynamic tumor biology.

We read the signals above the noise.

Exai uses artificial intelligence (AI) and machine learning (ML) to interpret the thousands of oncRNAs found in the blood of patients with cancer by identifying unique, cancer-specific patterns.

Exai has shown that oncRNA patterns can be used to detect several types and subtypes of cancer, predict cancer tissue-of-origin and detect cancer at the earliest stages. In a study using blood samples from patients with breast cancer, changes in oncRNAs reflected therapy response, predicted overall survival and added significant information to other clinical endpoints such as tumor tissue pathology.

Read the Publication >

ADVANTAGE

the Exai advantage.

We are looking where others are not.

The abundance of oncRNAs in the blood of patients with cancer allows the use of small amounts of blood and enables access to large, archival cohorts for the rapid execution of a variety of studies. From these samples, Exai has created a catalog of over 200,000 oncRNAs that establish a foundation for test development.

Read the Abstract >

DISCOVERY

a novel approach to liquid biopsy.

We are looking where others are not.

In studies of more than 10,000 subjects, Exai has identified hundreds of thousands of unique oncRNAs, which comprise an extensive catalog that is enabling Exai to develop novel RNA-based tests for early cancer detection.

INSIGHTS

AI empowers oncRNAs to reveal dynamic tumor biology.

We read the signals above the noise.

Exai uses artificial intelligence (AI) and machine learning (ML) to interpret the thousands of oncRNAs found in the blood of patients with cancer by identifying unique, cancer-specific patterns.

Advantage

the Exai advantage.

Exai is moving rapidly with a robust R&D program in multiple cancers.

Our Science

a novel approach to liquid biopsy.

AI empowers oncRNAs to reveal dynamic tumor biology.

the Exai advantage.

a novel approach to liquid biopsy.

AI empowers oncRNAs to reveal dynamic tumor biology.

the Exai advantage.

Mission